Concepedia

Author

Peter Johnson

University of SouthamptonORCID

Also Known As

Alison Jones, Benjamin Kwan, Gary Middleton, Gavitt Woodard, Johnson, P, Johnson, P M, Johnson, P., Johnson, PMW, Johnson, PWM, Johnson, Peter

1.1K

Publications

39.9K

Citations

99

H-Index

405

Concepts

All Affiliations

University of SouthamptonCancer Research UKUniversity of LiverpoolSouthampton General HospitalUniversity College London
PJ

About

Peter Johnson is an author at University of Southampton specializing in medicine, immunology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

19

24

2.7K

2

Engineering

11

12

521

3

Business

5

5

134

4

Management

4

4

102

5

Humanities

1

1

13

Peter Johnson

×

398

Publications

34.2K

Citations

91

H-Index

YearCitations

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin,

New England Journal of Medicine

2013

1.7K

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hervé Tilly, María Gomes da Silva, Umberto Vitolo,

Annals of Oncology

2015

900

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer,

PubMed

1998

896

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

Peter Johnson, Massimo Federico, Amy A. Kirkwood,

New England Journal of Medicine

2016

778

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

John Radford, Tim Illidge, Nicholas Counsell,

New England Journal of Medicine

2015

734

XRCC1 Polypeptide Interacts with DNA Polymerase   and Possibly Poly (ADP-Ribose) Polymerase, and DNA Ligase III Is a Novel Molecular 'Nick-Sensor' In Vitro

Keith W. Caldecott, Saïd Aoufouchi, Peter Johnson,

Nucleic Acids Research

1996

609

Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

Ash Kieran Clift, Carol Coupland, Ruth H. Keogh,

BMJ

2020

602

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson,

Journal of Clinical Oncology

2019

591

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski,

The Lancet Haematology

2016

582

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack,

The Lancet

2013

546

Page 1